165 studies found for:    "Peripheral T-cell lymphoma"
Show Display Options
Rank Status Study
1 Terminated Lenalidomide Therapy for Patients With Relapsed and/or Refractory, Peripheral T-Cell Lymphomas
Conditions: Peripheral T-cell Lymphomas;   Adult T-cell Leukemia;   Adult T-cell Lymphoma;   Peripheral T-cell Lymphoma Unspecified;   Angioimmunoblastic T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   T/Null Cell Systemic Type;   Cutaneous t-Cell Lymphoma With Nodal/Visceral Disease
Intervention: Drug: Lenalidomide
2 Active, not recruiting Romidepsin in Combination With CHOEP as First Line Treatment Before Hematopoietic Stem Cell Transplantation in Young Patients With Nodal Peripheral T-cell Lymphomas: a Phase I-II Study
Conditions: Peripheral T-cell Lymphomas (PTCL);   Peripheral T-cell Lymphomas Not Otherwise Specified (PTCL-NOS),;   Angioimmunoblastic T-cell Lymphoma (AITL);   ALK- Anaplastic Largecell Lymphoma (ALCL).
Interventions: Drug: Ro-CHOEP-21 (PHASE I);   Drug: Ro-CHOEP-21 (PHASE II)
3 Recruiting Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma
Conditions: Relapsed Peripheral T-Cell Lymphoma;   Refractory Peripheral T-Cell Lymphoma
Interventions: Drug: Alisertib;   Drug: Pralatrexate;   Drug: Gemcitabine;   Drug: Romidepsin
4 Recruiting Treatment of Peripheral T-cell Lymphoma
Condition: Peripheral T-cell Lymphoma
Interventions: Drug: GDPT regimen;   Drug: CHOP regimen
5 Active, not recruiting Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma
Condition: Peripheral T-cell Lymphoma
Intervention: Drug: PXD101
6 Completed CHO(E)P-14 Followed by Alemtuzumab Consolidation in Peripheral T Cell Lymphoma
Condition: Peripheral T-Cell Lymphoma
Intervention: Drug: Alemtuzumab
7 Unknown  Study of Bortezomib Combined With ACVBP in Peripheral T-Cell Lymphoma
Condition: Peripheral T-Cell Lymphoma
Intervention: Drug: Velcade + ACVBP regimen
8 Recruiting Pilot Study of Brentuximab Vedotin in Relapsed/Refractory Peripheral T-Cell Lymphoma Expressing CD30
Condition: Peripheral T-Cell Lymphoma
Intervention: Drug: Brentuximab vedotin
9 Active, not recruiting
Has Results
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
Condition: Peripheral T-cell Lymphoma
Intervention: Drug: Romidepsin
10 Active, not recruiting Study of KW-0761 (Mogamulizumab) in Subjects With Previously Treated Peripheral T-cell Lymphoma (PTCL)
Condition: Peripheral T-Cell Lymphoma
Intervention: Biological: KW-0761 (mogamulizumab)
11 Completed
Has Results
Study of Pralatrexate With Vitamin B12 and Folic Acid in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
Condition: Peripheral T-cell Lymphoma
Intervention: Drug: Pralatrexate Injection
12 Completed Study of Bortezomib and Panobinostat in Treating Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma
Conditions: Peripheral T-cell Lymphoma (Not Otherwise Specified);   Angioimmunoblastic T-cell Lymphoma;   Extranodal NK/T-cell Lymphoma Nasal Type;   Enteropathy- Type T-cell Lymphoma;   Hepatosplenic T-cell Lymphoma;   Anaplastic Large Cell Lymphoma (ALCL) (ALK-1 Negative);   Relapsed ALCL (ALK-1 Positive) Post Autologous Transplant
Intervention: Drug: panobinostat and bortezomib
13 Recruiting E7777 for the Treatment of Patients With Peripheral T-Cell Lymphoma
Condition: Peripheral T-Cell Lymphoma
Intervention: Biological: denileukin diftitox (E7777)
14 Active, not recruiting Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
Condition: Peripheral T-cell Lymphoma
Intervention:
15 Active, not recruiting Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma
Conditions: Cutaneous T Cell Lymphoma;   Peripheral T Cell Lymphoma
Intervention: Drug: Romidepsin
16 Completed Study About Treatment of Newly Diagnosed Non Cutaneous Peripheral T Cell Lymphoma
Condition: Peripheral T Cell Lymphoma
Interventions: Drug: CHOP21;   Drug: VIP/ABVD;   Radiation: Radiotherapy consolidation
17 Active, not recruiting Treatment of Peripheral T-cell Lymphoma With Aggressive Induction Chemotherapy Followed by Autologous Stem Cell Transplant Using Denileukin Diftitox (Ontak)
Condition: Peripheral T-Cell Lymphoma
Interventions: Drug: REGIMEN;   Drug: REGIMEN B
18 Active, not recruiting Alemtuzumab and CHOP Chemotherapy for Aggressive Histological Peripheral T-Cell Lymphomas
Condition: Peripheral T-cell Lymphomas
Intervention: Drug: Alemtuzumab (Campath-1H)
19 Recruiting A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL)
Condition: Peripheral T-cell Lymphoma
Intervention: Drug: SP-02L (darinaparsin for injection)
20 Recruiting Phase I/II Clinical Study of Pralatrexate in Japanese Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
Condition: Peripheral T-cell Lymphoma
Interventions: Drug: Pralatrexate injection;   Dietary Supplement: Vitamin B12;   Dietary Supplement: Folic Acid

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years